BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma

James S. Wilmott; Alexander M. Menzies; Lauren E. Haydu; David Capper; Matthias Preusser; Ying E. Zhang; John F. Thompson; Richard Kefford; Andreas von Deimling; Richard A Scolyer; Georgina V. Long

doi:10.1038/bjc.2013.29

Related publications

Article2013

Intrapatient Homogeneity of BRAFV600E Expression in Melanoma

Alexander M. Menzies, Trina Lum, James S. Wilmott, Jessica Hyman, Richard Kefford, John F. Thompson, Sandra A. O’Toole, Georgina V. Long, Richard A Scolyer

Article2012

Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma

Georgina V. Long, James S. Wilmott, David Capper, Matthias Preusser, Yuxiao E. Zhang, John F. Thompson, Richard Kefford, Andreas von Deimling, Richard A Scolyer

Article2014

Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment

James S. Wilmott, Lauren E. Haydu, Alexander M. Menzies, Trina Lum, Jessica Hyman, John F. Thompson, Peter Hersey, Richard Kefford, Richard A Scolyer, Georgina V. Long

Article2014

Correlation between pre-existing MEK1<sup>P124</sup> mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma.

Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Richard A Scolyer, Richard Kefford, Georgina V. Long, Helen Rizos

Preprint2023

Supplementary Figures 1 - 9 from BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, Richard F. Kefford, Richard A Scolyer, Georgina V. Long